Cargando…

PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242

A deeper understanding of the complex pathogenesis of multiple myeloma (MM) continues to lead to novel therapeutic approaches. Prior studies suggest that 3-phosphoinositide-dependent kinase 1 (PDK1) is expressed and active, acting as a crucial regulator of molecules that are essential for myelomagen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chunmei, Huang, Xianbo, Liu, Hui, Xiao, Feng, Wei, Jueying, You, Liangshun, Qian, Wenbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503605/ https://www.ncbi.nlm.nih.gov/pubmed/28402933 http://dx.doi.org/10.18632/oncotarget.16642

Ejemplares similares

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt
por: Meng, Haitao, et al.
Publicado: (2013)

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
por: Du, Heng, et al.
Publicado: (2023)

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009)

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
por: Burnett, G. Leslie, et al.
Publicado: (2022)

Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors
por: Faes, Seraina, et al.
Publicado: (2016)

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
por: Abdallah, Chadi G., et al.
Publicado: (2020)

Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells
por: Sandoval, Jose A., et al.
Publicado: (2020)

mTORC1 is necessary but mTORC2 and GSK3β are inhibitory for AKT3-induced axon regeneration in the central nervous system
por: Miao, Linqing, et al.
Publicado: (2016)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

SAT-059 Treatment Of Primary Aldosteronism With The mTORC1 Inhibitor Everolimus
por: Trinh, Beckey, et al.
Publicado: (2019)

Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury
por: Li, Hui, et al.
Publicado: (2021)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
por: Zhang, Hao, et al.
Publicado: (2013)

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013)

A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
por: Mateo, Joaquin, et al.
Publicado: (2016)

RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes
por: Weinberg, Mark A.
Publicado: (2016)

Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors
por: Lee, Dongjun, et al.
Publicado: (2014)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
por: Castel, Pau, et al.
Publicado: (2016)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
por: Mahoney, Sarah J., et al.
Publicado: (2018)

Enhancing TFEB-Mediated Cellular Degradation Pathways by the mTORC1 Inhibitor Quercetin
por: Huang, Yi, et al.
Publicado: (2018)

Activation of lysosomal mediated cell death in the course of autophagy by mTORC1 inhibitor
por: Khan, Sameer Ullah, et al.
Publicado: (2022)

mTORC1 and SGLT2 Inhibitors—A Therapeutic Perspective for Diabetic Cardiomyopathy
por: Saha, Sumit, et al.
Publicado: (2023)

PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT
por: Mecca, Carmen, et al.
Publicado: (2018)

Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
por: Rogers-Broadway, Karly-Rai, et al.
Publicado: (2019)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Regulation of adiposity by mTORC1
por: Magdalon, Juliana, et al.
Publicado: (2017)

mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
por: Walters, Hannah E., et al.
Publicado: (2018)

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
por: Le Tourneau, C, et al.
Publicado: (2008)

Screen for Chemical Modulators of Autophagy Reveals Novel Therapeutic Inhibitors of mTORC1 Signaling
por: Balgi, Aruna D., et al.
Publicado: (2009)

Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect
por: Sousa-Victor, Pedro, et al.
Publicado: (2015)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fbqno3ob5mu8rtpsiadcs4c0lc